Previous 10 | Next 10 |
2023-03-30 16:38:01 ET Pulse Biosciences press release ( NASDAQ: PLSE ): Q4 GAAP EPS of -$0.25 misses by $0.01 . For further details see: Pulse Biosciences GAAP EPS of -$0.25 misses by $0.01
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced financial results for the fourth quarter and full year ended December ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year ...
The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to integrate its iMap System with the nsPFA System to demonstrate the benefits of a...
Pulse Biosciences ( NASDAQ: PLSE ) disclosed in a filing on Tuesday that chief financial officer Sandra Gardiner gave notice of her resignation on November 30. The company said it has began a search for a new CFO to succeed Gardiner. Shares -7.9% after the bell. ...
Pulse Biosciences ( NASDAQ: PLSE ) CFO Sandra Gardiner is resigning from the bioelectric medicine company . Pulse ( PLSE ) said her departure was not the result of any disagreements or matters related to policies or practices. The company will soon begin a search for her r...
Pulse Biosciences, Inc. (PLSE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief T...
Pulse Biosciences press release ( NASDAQ: PLSE ): Q3 GAAP EPS of -$0.49. Cash and cash equivalents totaled $69.2 million as of September 30, 2022 compared to $28.6 million as of December 31, 2021 and $14.8 million as of June 30, 2022. For further details see: Pul...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™ (NPS™) to human cells and tissue for ablation in multiple therapeu...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on T...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the fi...
2024-06-25 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...